Morgan Stanley upgraded Kymera Therapeutics, Inc. (NASDAQ:KYMR) to "Overweight" with a price target raised to $73.Kymera reported a quarterly loss of $0.90 per share, missing the Zacks Consensus Estimate by 26.76%.The company's revenue for Q3 2025 was $2.76 million, falling short of expectations by 89.6%.Kymera Therapeutics, Inc. (NASDAQ:KYMR) is a biopharmaceutical company focused on developing novel protein degradation therapies. Operating in the Zacks Medical - Biomedical and Genetics industry, Kymera ai ...